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ABSTRACT
Background Anxiety disorder, one of the highly disabling, 
prevalent and common mental disorders, is known to be 
more prevalent in persons with type 2 diabetes mellitus 
(T2DM) than the general population, and the comorbid 
presence of anxiety disorders is known to have an impact 
on the diabetes outcome and the quality of life. However, 
the information on the type of anxiety disorder and its 
prevalence in persons with T2DM is limited.
Aims To assess the prevalence and correlates of anxiety 
disorder in people with type 2 diabetes in different 
countries.
Methods People aged 18–65 years with diabetes 
and treated in outpatient settings were recruited in 
15 countries and underwent a psychiatric interview 
with the Mini-International Neuropsychiatric Interview. 
Demographic and medical record data were collected.
Results A total of 3170 people with type 2 diabetes 
(56.2% women; with mean (SD) duration of diabetes 
10.01 (7.0) years) participated. The overall prevalence of 
anxiety disorders in type 2 diabetic persons was 18%; 
however, 2.8% of the study population had more than 
one type of anxiety disorder. The most prevalent anxiety 
disorders were generalised anxiety disorder (8.1%) 
and panic disorder (5.1%). Female gender, presence of 
diabetic complications, longer duration of diabetes and 
poorer glycaemic control (HbA1c levels) were significantly 
associated with comorbid anxiety disorder. A higher 
prevalence of anxiety disorders was observed in Ukraine, 
Saudi Arabia and Argentina with a lower prevalence in 
Bangladesh and India.
Conclusions Our international study shows that 
people with type 2 diabetes have a high prevalence of 
anxiety disorders, especially women, those with diabetic 
complications, those with a longer duration of diabetes 
and poorer glycaemic control. Early identification and 
appropriate timely care of psychiatric problems of people 
with type 2 diabetes is warranted.
InTRoduCTIon
Anxiety disorders are characterised by exces-
sive worries, hyperarousal states and fear, 
which are counterproductive and debili-
tating.1 The global prevalence of anxiety 
disorder in the general population is about 
7.3% (4.8%–10.9%),2 and it is one of the 
leading causes of disability with 390 disabil-
ity-adjusted life years per 100 000 persons.3 
Anxiety disorders mainly comprise gener-
alised anxiety disorder (GAD), panic disorder, 
agoraphobia, social phobia, obsessive-com-
pulsive disorder (OCD) and post-traumatic 
stress disorder (PTSD). Recent high-quality 
studies,4–9 including a systematic review,10 
have reported a higher prevalence and inci-
dence of anxiety disorders in people with 
type 2 diabetes mellitus compared with the 
general population. It has also been suggested 
that there may be a bidirectional relationship 
between these two disorder conditions.11 12 
Female sex, younger age, low socioeconomic 
status and concomitant chronic illnesses are 
particular vulnerability factors for developing 
anxiety disorders.5 13 14 The most prevalent 
anxiety disorders in people with diabetes 
mellitus are GAD (21%), social phobia (7%) 
and panic disorder (2.5%).15 A substan-
tial proportion of people with diabetes also 
exhibit higher subsyndromal anxiety and 
elevated anxiety symptoms.10 14 16 In diabetes, 
anxiety is associated with poor glycaemic 
control,16–20 increased risk of diabetes-related 
complications, increased risk of stroke21 and 
poor quality of life,22 23 which may improve 
with anxiolytics and non-pharmacological 
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treatments.24–26 Hence, it is essential to identify and 
address anxiety in persons with diabetes early on, in order 
to reduce the burden of comorbid disease, improve blood 
glucose control and therefore reduce the risk of diabetes 
complications.
There are wide variations in the prevalence of anxiety 
disorders across countries and within, which could be 
due to heterogeneous study samples, the use of different 
assessment tools and even using different cut-off levels 
within the same scales. In addition, many studies have 
reported the presence of both elevated anxiety symp-
toms and the syndromal anxiety disorders with less clear 
distinction between them.14 16
More specifically, the prevalence of anxiety symp-
toms in patients with type 2 diabetes using the Hospital 
Anxiety and Depression Scale in Pakistan was reported 
to be around 57.9%,27 with a much lower prevalence of 
9% in Germany.28 In Saudi Arabia, the prevalence of 
psychiatric disorders in the general population is still 
unknown. However, the prevalences of primary anxiety 
disorders among inpatient and outpatient psychiatric 
patients in Saudi Arabia have been reported as 1.6% and 
16.3%, respectively.29 With regard to diabetes popula-
tions in Saudi Arabia (which has one of the highest prev-
alence rates of type 2 diabetes), studies have reported the 
prevalence of significant anxiety symptoms to be 28.5%, 
which was higher in women, those smoking, with a longer 
duration of diabetes and being unmarried.30 Another 
study in Saudi Arabia, using the Hamilton Anxiety Scale, 
reported a prevalence of 3.3% of people with diabetes 
compared with 5% of controls with no significant differ-
ence.31 Among hospitalised patients with type 2 diabetes 
50.6% were identified as suffering from anxiety which 
was independently associated with physical inactivity.9 
Approximately similar prevalence rates were observed 
in two studies of patients with type 2 diabetes, with phys-
ical inactivity and poor social support being explanatory 
factors.9 10
In Poland, a nationwide study conducted between 2010 
and 2011 on a large population of 10 081 persons aged 
18–64 showed the prevalence of different anxiety disor-
ders to be between 0.1% and 6.2%;32 however, there 
are no reports of anxiety in persons with diabetes. In 
contrast, one study in Russia observed a much higher rate 
of anxiety disorders of 60%.33 Diabetes-specific phobias 
(phobias of needles, blood, hypoglycaemia) were also 
observed in 1.7%.34 These studies have combined people 
with type 1 and type 2 diabetes so it is difficult to infer the 
exact prevalence and association of anxiety disorders in 
each of the subtypes of diabetes.
In a collaborative study across 15 countries differing in 
socioeconomic status, cultural background and levels of 
healthcare services, we aimed to study the prevalence and 
treatment of comorbid anxiety disorder in a large cohort 
of people with type 2 diabetes. The same study protocol 
was used across the countries which included both a clin-
ical interview and a screening instrument to detect clini-
cally significant anxiety.35
MeThodS
A full description of the protocol of the International 
Prevalence and Treatment of Diabetes and Depres-
sion (INTERPRET-DD) study used in the present study 
is provided in earlier papers.35 36 In brief, consecutive 
outpatient clinic attendees with type 2 diabetes, diag-
nostic criteria according to WHO criteria (random 
plasma glucose ≥11.1 mmol/L or fasting plasma glucose 
≥7.0 mmol/L or 2-hour plasma glucose ≥11.1 mmol/L), 
at each of the study sites were invited to participate in 
the study between September 2013 and May 2015. Site 
investigator teams were recruited from leading centres 
of excellence in each country, which included at least 
one psychiatrist and endocrinologist for each country. 
The treating physician/diabetologist in the diabetes 
clinic invited individuals to participate in the study. 
Diabetes clinics were based in either secondary or tertiary 
care centres, depending on the facilities available in 
each country. However, from Pakistan, another centre 
from primary care was also included. The observations 
presented here pertain to the first cross-sectional assess-
ment of the subjects during the first intake.
Inclusion/exclusion criteria
Full details of the eligibility criteria have been described 
elsewhere.35 36 In brief, the participants were adults (aged 
18–65 years) with type 2 diabetes diagnosed at least 12 
months before the point of contact at the diabetes outpa-
tient facilities. Detailed medical records and sociodemo-
graphic details of the participants were obtained.
A psychiatric interview was conducted by a trained inter-
viewer using the Mini-International Neuropsychiatric 
Interview (MINI, version 5 or version 6 depending on the 
current psychiatric practice at the study site).37 The MINI 
is a reliable diagnostic tool that has been widely used in a 
range of different populations, suitable for subjects with 
serious illness as well as in community surveys, and is in 
accordance with the Diagnostic and Statistical Manual 
of Mental Disorders Fifth Edition criteria.38 Individuals 
diagnosed with anxiety disorders were advised to consult 
their physician for further assessment and treatment. In 
the case of any psychiatric emergencies such as suicidal 
risk,the interviewing psychiatrist initiated immediate 
appropriate clinical care.
Statistical analysis
SPSS V.2339 was used to analyse the data. Comparative 
profiles of demographic and clinical variables between 
people with type 2 diabetes with and without anxiety 
disorder were examined using independent samples t-test 
or χ2 test as applicable.
ReSulTS
A total of 3170 people with type 2 diabetes (56.2% women; 
mean (SD) duration of diabetes 10.01 (7.0) years) partic-
ipated (see figure 1). The mean (SD) age of the study 
population was 53.43 (9.52) years.
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Figure 1 Flowchart of the sample recruitment.
The prevalence of anxiety disorders in type 2 diabetes 
persons was 18% (table 1). The most common anxiety 
disorders were GAD (8.5%) and lifetime panic disorder 
(5.1%). More than one type of anxiety disorders were 
observed in 2.8% of the study population. Only 4% of 
the study subjects had more than one psychiatric disorder 
like dysthymia or major depressive episode.
Particularly Ukraine, Saudi Arabia and Argentina 
showed higher rates of anxiety disorders (72.7%, 52.2% 
and 37.6%, respectively) whereas prevalences were found 
to be lower/absent in India and Bangladesh (0.5% and 
0.0%, respectively) as shown in table 1. These differ-
ences were statistically different between the countries. 
However, it is not possible to compute these differences 
for different types of anxiety disorders in different coun-
tries due to small (or absent) numbers in many categories 
in different countries.
Female gender was positively associated with all anxiety 
disorders (table 2).
Presence of GAD (t=3.08, p=0.002) and current panic 
disorder (t=1.98, p=0.04) as well as lifetime panic disorder 
(t=2.21, p=0.027) were all significantly associated with 
poorer glycaemic control as indicated by HbA1c levels 
compared with participants without anxiety disorders 
(table 3).
Duration of diabetes was positively correlated with 
the presence of GAD (t=4.645, p=0.00), OCD (t=2.064, 
p=0.039) and PTSD (t=3.201, p=0.001) (table 4).
Those with anxiety disorders except OCD showed statis-
tically significantly higher rates of diabetic complications 
than those without anxiety disorders (table 5). The 
diabetic complications recorded were mainly in the form 
of diabetic nephropathy and neuropathy. Almost half 
the subjects had one or more diabetes-related medical 
complications as reported in our previous study on the 
same subject samples.35
dISCuSSIon
Main findings
In our study we observed a substantially high prevalence 
of anxiety disorder (18%) in people with type 2 diabetes. 
The most prevalent anxiety disorders were found to be 
GAD and panic disorder. Some countries had statistically 
higher rates of anxiety disorders than others. However, 
whether these statistical differences reflect differences in 
the overall rates in these countries is difficult to comment 
as the general population prevalence of anxiety disorders 
in all the countries is not available. Female gender, the 
presence of diabetes complications, longer duration of 
diabetes and poorer glycaemic control were all observed 
to be correlates of anxiety disorders, however there was 
wide variation of occurrence of anxiety disorders across 
the 15 countries studied. The predominance of anxiety 
disorders in females with diabetes may be a reflection 
of the overall pattern for anxiety disorders. This study 
identified differences in the prevalence of anxiety symp-
toms, as well as the clinical diagnosis of anxiety disorders 
among the countries. Similar observations were described 
in the report on depressive disorders in diabetes mellitus, 
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Table 2 Gender differences across anxiety disorders in people with diabetes
Gender
χ2 P value
Female
n (% of total sample)
Male
n (% of total sample)
GAD (current) 193 (6.1) 77 (2.4) 27.78 <0.001
Panic disorder (current) 80 (2.5) 40 (1.3) 5.43 0.020
Agoraphobia 84 (2.7) 26 (0.8) 18.71 <0.001
OCD 36 (1.1) 7 (0.2) 13.32 <0.001
Social phobia 60 (1.9) 21 (0.7) 10.71 <0.001
Panic disorder (lifetime) 118 (3.7) 43 (1.4) 19.96 <0.001
GAD, generalised anxiety disorder; OCD, obsessive-compulsive disorder.
Table 3 Diabetic control (HbA1c %) by anxiety disorders
HbA1c % in those with 
anxiety disorders
n (mean (SD))
HbA1c % in those without 
anxiety disorders
n (mean (SD))
T-test 
statistics P value 95% CI
GAD 215
(8.79 (2.45))
2074
(8.27 (2.36))
−3.08 0.002 0.86 to 0.19
Panic disorder (current) 109
(8.76 (2.05))
2179
(8.30 (2.39))
−1.98 0.040 0.90 to 0.00
Agoraphobia 98
(8.45 (2.21))
2192
(8.31 (2.380))
−0.52 0.580 0.61 to 0.34
OCD 39
(8.69 (2.27))
2251
(8.31 (2.38))
−0.99 0.320 1.13 to 0.37
Social phobia 73
(8.78 (2.32))
2217
(8.30 (3.28))
−1.70 0.088 1.03 to 0.72
Panic disorder (lifetime) 149
(8.73 (2.36))
2141
(8.29 (2.38))
−2.21 0.027 0.84 to 0.05
GAD, generalised anxiety disorder; OCD, obsessive-compulsive disorder.
in this same sample group.35 This may reflect differences 
in the acceptance/stigma of acknowledging symptoms of 
psychological and emotional distress in different cultural 
groups. It is difficult to speculate whether the different 
rates can be attributed to between-country characteristics, 
as this aspect was not studied in detail.35 The exact ratio 
of anxiety disorders in the general population of each 
country was not available to derive any conclusive infer-
ence about the effect of gender on occurrence of anxiety 
disorders in people with diabetes. We observed a high 
percentage of anxiety disorders in the Russian sample 
which may be caused by the relatively higher proportion 
of women in the sample, which was 76.5%. The detec-
tion of anxiety disorders in women compared with men 
was higher, especially in agoraphobia (16.3% vs 6.4%). 
The increased frequency of anxiety disorders in partici-
pants from Russia may be related to the high frequency 
of PTSD, which reached 7.5%.
The findings of this study make an important contribu-
tion to the evidence of occurrence of anxiety disorders 
in people with type 2 diabetes. In particular, we have 
used the same methodology for identification across all 
the countries and so comparisons are more appropriate. 
Similar findings were reported in studies from the USA40 
and others on higher risk of development and prevalence 
of anxiety disorders in persons with diabetes.10 12 15 41 
However, there is wide variation in prevalence of anxiety 
disorders across studies which could be due to differences 
in methodology such as the tools used for assessment, 
ethnic background, cultural variation or diabetes-related 
factors.10
Like other studies,14 22 we have observed wide differ-
ences in rates of anxiety disorders across the 15 countries, 
with higher rates in countries such as Ukraine, Saudi 
Arabia and Argentina, and lower rates in countries such 
as India, Bangladesh and Pakistan. It is interesting to note 
that the rates of anxiety disorders in this study were lower 
than the World Mental Health Survey (WMHS) initia-
tive42 in two countries, Germany and Italy, and markedly 
higher in another two countries, namely Ukraine and 
Mexico. In the clinical sample in this study, we would 
have expected higher rates compared with the general 
population sample in WMHS, but the findings do not 
indicate this consistently. The differences between coun-
tries that we have observed could be speculated to be due 
to cultural differences in the reporting and experience 
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Table 4 Duration of diabetes by anxiety disorders
Yes
n (mean (SD))
No
n (mean (SD)) T-test statistics P value 95% CI
GAD 268 (11.91 (7.87)) 2884 (9.83 (6.90)) −4.64 <0.001 1.19 to 0.44
Panic disorder 
(current)
120 (10.83 (6.52)) 3031 (9.98 (7.03)) −1.29 0.194 0.43 to 0.65
Agoraphobia 109 (10.05 (6.86)) 3043 (10.01 (7.01)) 0.05 0.955 1.30 to 0.68
Social phobia 81 (10.32 (6.12)) 3071 (10.01 (7.03)) 0.39 0.694 1.23 to −0.31
OCD 43 (12.20 (7.45)) 3109 (9.98 (7.00)) −2.06 0.039 −0.11 to 1.07
Panic disorder 
(lifetime)
161 (10.59 (7.18)) 2992 (9.98 (7.00)) −1.06 0.287 0.50 to 0.56
GAD, generalised anxiety disorder; OCD, obsessive-compulsive disorder.
Table 5 Diabetes complications by anxiety disorder
Diabetic complication χ2 statistic P value
Yes
n (% of total sample)
No
n (% of total sample)
GAD (current) 154 (5.3) 93 (3.2) 9.21 0.002
Panic disorder 82 (2.8) 32 (1.1) 16.75 <0.001
Agoraphobia 69 (2.4) 39 (1.3) 5.21 0.022
Social phobia 52 (1.8) 25 (0.9) 6.56 0.010
OCD 26 (0.9) 15 (0.5) 1.76 0.185
Panic disorder (lifetime) 100 (3.4) 55 (1.9) 8.50 0.004
GAD, generalised anxiety disorder; OCD, obsessive-compulsive disorder.
of anxiety symptoms, possibly due to the stigma associ-
ated with having a mental health problem or due to the 
extensive social support offered by families in some coun-
tries which may aid onset prevention. In addition, anxiety 
disorders in the general population have been reported 
to be less prevalent in the Indo/Asian countries than in 
the rest of the world,13 which supports our findings. A 
South American country (Brazil) has reported a much 
higher prevalence of GAD and panic disorder compared 
with the prevalence we observed in Argentina. This 
difference could be due to differences in diabetes dura-
tion (the Brazilian study only included people with more 
than 5 years of diabetes compared with the current study 
in which participants are included with at least 1 year of 
diabetes). In our study, duration of diabetes was a signifi-
cant factor associated with anxiety disorders.
The results in the sample of patients from Poland show 
a strikingly higher prevalence of anxiety disorders in 
persons with type 2 diabetes in comparison to the general 
population. The prevalence of social phobia was over 
three times higher, GAD almost 10 times higher, panic 
disorder almost 14 times higher and agoraphobia almost 
19 times higher in persons with type 2 diabetes when 
compared with the most recent data from a large sample 
of the general population.32 With the current method-
ology, it is difficult to speculate on the possible reasons 
for this observation.
Our findings of a relationship between symptoms of 
anxiety and other physical comorbidities, along with 
poorer glycaemic control, support the findings of other 
countries mentioned above. In our previous report on 
this study sample, insulin use was reported by 41.8%, and 
50.8% of subjects reporting one or more complications.35
limitations
As in other studies, the present study also has some limita-
tions. First, the severity of the anxiety disorders was not 
measured. Second, details about the use of psychotropic 
medications for the persons with clinically significant 
anxiety which could have provided an indirect measure 
of severity of the symptoms were not available. Third, 
details about insulin requirements for the management 
of diabetes could have given information as to whether 
the psychological distress related to use of insulin has an 
impact on the anxiety symptoms.43 Although the assess-
ments and interviews were conducted by trained and 
qualified interviewers, the inter-rater reliability between 
the interviewers was not attempted due to the location 
of centres across the 15 countries. In our follow-up study, 
we will be able to examine the longitudinal associations 
of the use of psychotropic medications or non-pharma-
cological management of anxiety disorders on glycaemic 
control. Fourth, because the present study took place in 
specialty clinics, which may not be representative of the 
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wider population of people with diabetes, the prevalence 
rates in the present study cannot be generalised to the 
wider diabetes population.
Implications
The INTERPRET-DD study has a number of strengths. 
It was a collaborative study of the prevalence of anxiety 
disorders in people with type 2 diabetes, carried out at the 
same time using the same protocol in 15 different coun-
tries. This study included more than 3000 people with 
a clinical diagnosis of type 2 diabetes,35 36 and is meth-
odologically strong with the use of a reliable diagnostic 
tool for identifying anxiety disorders implemented by 
trained interviewers. In addition, the investigators in each 
country ensured that the diagnostic tools were culturally 
applicable through a series of discussions and testing by a 
range of healthcare professionals and people with type 2 
diabetes, which focused on the meaning of terms as well 
as language.
ConCluSIon
This report presents the cross-sectional findings on the 
occurrence of anxiety disorders, hence, it is difficult to 
comment on whether the anxiety disorder is a complica-
tion or sequelae of diabetes, or just a comorbid psychiatric 
condition. It is not possible to comment on which anxiety 
disorders were present prior to diagnosis of diabetes, 
and which were a consequence of having diabetes. The 
result of our prospective follow-up study is likely to shed 
light on this aspect. It is essential to pay additional atten-
tion to mental health issues such as anxiety in persons 
with diabetes to ensure better quality of life22 and better 
glycaemic control,44 and to lessen the burden of diabe-
tes-related complications.21 45 It is likely that anxiety 
may be a protective factor for diabetes complications as 
anxious people may consult more for minor symptoms 
and ailments.46
Anxiety disorder was observed in 18% of people with 
type 2 diabetes. Factors associated with higher prevalence 
of anxiety disorders were female gender, longer duration 
of diabetes, more diabetes complications and poorer 
diabetic control. The International Diabetes Federation 
recommends regular screening for psychological prob-
lems such as depression,47 and the findings of this present 
study extend this to anxiety. Hence, it is important to 
identify and address the comorbid anxiety in persons 
with diabetes at the earliest in order to offer psycholog-
ical interventions which could improve diabetic control, 
so reducing the risk of developing diabetes complications 
which have negative consequences for quality of life.
Author affiliations
1Department of Psychiatry, National Institute of Mental Health and Neuro-Sciences, 
Bangalore, India
2Child Adolescent and Family Psychiatry, National Institute of Mental Health, Dhaka, 
Bangladesh
3Department of Psychiatry, King Saud University, Riyadh, Saudi Arabia
4IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Italy
5National Research Centre for Psychiatry and Narcology, Moscow, Russia
6IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
7University of Milano-Bicocca, Bicocca, Italy
8Department of Psychology, Catholic University, Milan, Italy
9Department of Psychiatry, Wroclaw Medical University, Wroclaw, Poland
10Institute of Mental Health, Belgrade, Serbia
11Samatvam Endocrinology Diabetes Center and Jnana Sanjeevini Diabetes Hospital 
and Medical Center, Bangalore, India
12University of Lower Silesia, Wroclaw, Poland
13Center for Global Mental Health, Rawalpindi, Pakistan
14University of Nairobi, Nairobi, Kenya
15Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
16Pakistan Institute of Medical Sciences, Islamabad, Pakistan
17Department of Psychiatry and Psychotherapy, Medical Faculty, University of 
Düsseldorf, Dusseldorf, Germany
18ProConsult, Owings Mills, Maryland, USA
Authors contributions SKC and SMG analysed the data and prepared the first 
draft of the manuscript. All authors from the 15 countries contributed to the study in 
its planning, data collection and analysis. All authors contributed to the manuscript 
and approved the final versions.
Funding Statement The authors have not declared a specific grant for this 
research from any funding agency in the public, commercial or not-for-profit 
sectors.
Competing interests AB has received a research grant from Abbott, and fees 
for lectures from Lundbeck. CL has received travel expenses paid by unrestricted 
grants from Eli Lily and Sanofi to attend the World Diabetes Congress and the 
American Psychiatric Association conference. The Association for the Improvement 
of Mental Health Programs, which sponsored this programme and financially 
supported tasks related to its management and data analysis, received unrestricted 
grants from Eli Lilly and Sanofi. NS received travel support and fees from Janssen, 
Cilag, Lundbeck International Neuroscience Foundation, Servier: all outside the 
activities related to work on this study or on this paper. WW has received personal 
fees from Roche Pharma, outside the submitted work.
Patient consent for publication Not required.
eThICAl APPRoVAl Prior to commencing the study, ethical approval was obtained 
in all study settings. Ethical approval was also obtained from the Open University, 
UK, where the data were stored for analysis.
Provenance and peer review Not commissioned; externally peer reviewed.
data availability statement Data available at coordinating centre
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ReFeRenCeS
 1 Simpson HB, Neria Y, Lewis-Fernández R, et al. Anxiety 
DisordersTheory, research and clinical perspectives. Cambridge 
University Press, 2010.
 2 Baxter AJ, Scott KM, Vos T, et al. Global prevalence of anxiety 
disorders: a systematic review and meta-regression. Psychol Med 
2013;43:897–910.
 3 Baxter AJ, Vos T, Scott KM, et al. The global burden of anxiety 
disorders in 2010. Psychol Med 2014;44:2363–74.
 4 Huang C-J, Chiu H-C, Lee M-H, et al. Prevalence and incidence of 
anxiety disorders in diabetic patients: a national population-based 
cohort study. Gen Hosp Psychiatry 2011;33:8–15.
 5 Fisher L, Skaff MM, Mullan JT, et al. A longitudinal study of affective 
and anxiety disorders, depressive affect and diabetes distress in 
adults with type 2 diabetes. Diabet Med 2008;25:1096–101.
 6 Lin EHB, Von Korff M, Alonso J, et al. Mental disorders among 
persons with diabetes--results from the World Mental Health 
Surveys. J Psychosom Res 2008;65:571–80.
 7 Peyrot M, Rubin RR. Levels and risks of depression and 
anxiety symptomatology among diabetic adults. Diabetes Care 
1997;20:585–90.
8 Chaturvedi SK, et al. General Psychiatry 2019;32:e100076. doi:10.1136/gpsych-2019-100076
General Psychiatry
 8 Carroll D, Phillips AC, Thomas GN, et al. Generalized anxiety disorder 
is associated with metabolic syndrome in the Vietnam experience 
study. Biol Psychiatry 2009;66:91–3.
 9 Chaudhary R, Kumar P, Chopra A, et al. Comparative study of 
psychiatric manifestations among type I and type II diabetic patients. 
Indian J Psychol Med 2017;39:342–6.
 10 Smith KJ, Béland M, Clyde M, et al. Association of diabetes with 
anxiety: a systematic review and meta-analysis. J Psychosom Res 
2013;74:89–99.
 11 Chien I-C, Lin C-H. Increased risk of diabetes in patients with 
anxiety disorders: a population-based study. J Psychosom Res 
2016;86:47–52.
 12 Deschênes SS, Burns RJ, Schmitz N, et al. Associations between 
diabetes, major depressive disorder and generalized anxiety disorder 
comorbidity, and disability: findings from the 2012 Canadian 
Community Health Survey--Mental Health (CCHS-MH). J Psychosom 
Res 2015;78:137–42.
 13 Remes O, Brayne C, van der Linde R, et al. A systematic review of 
reviews on the prevalence of anxiety disorders in adult populations. 
Brain Behav 2016;6:e00497.
 14 Hermanns N, Kulzer B, Krichbaum M, et al. Affective and anxiety 
disorders in a German sample of diabetic patients: prevalence, 
comorbidity and risk factors. Diabet Med 2005;22:293–300.
 15 Maia ACCdeO, Braga AdeA, Brouwers A, et al. Prevalence of 
psychiatric disorders in patients with diabetes types 1 and 2. Compr 
Psychiatry 2012;53:1169–73.
 16 Grigsby AB, Anderson RJ, Freedland KE, et al. Prevalence of anxiety 
in adults with diabetes: a systematic review. J Psychosom Res 
2002;53:1053–60.
 17 Berlin I, Bisserbe JC, Eiber R, et al. Phobic symptoms, particularly 
the fear of blood and injury, are associated with poor glycemic 
control in type I diabetic adults. Diabetes Care 1997;20:176–8.
 18 Kojima K, Mohamed S, Fujimaru Y, et al. Effects of both the 
emotional behavior and feeding conditions on the circulating 
plasma volume and plasma glucose levels in cats. Auton Neurosci 
2000;86:58–64.
 19 Niemcryk SJ, Speers MA, Travis LB, et al. Psychosocial correlates of 
hemoglobin alc in young adults with type I diabetes. J Psychosom 
Res 1990;34:617–27.
 20 Turkat ID. Glycosylated hemoglobin levels in anxious and nonanxious 
diabetic patients. Psychosomatics 1982;23:1056–8.
 21 Tsai M-T, Erickson SR, Cohen LJ, et al. The association between 
comorbid anxiety disorders and the risk of stroke among patients 
with diabetes: an 11-year population-based retrospective cohort 
study. J Affect Disord 2016;202:178–86.
 22 Santos MABdos, Ceretta LB, Réus GZ, et al. Anxiety disorders are 
associated with quality of life impairment in patients with insulin-
dependent type 2 diabetes: a case-control study. Braz J Psychiatry 
2014;36:298–304.
 23 de Ornelas Maia ACC, Braga AdeA, Paes F, et al. Comorbidity 
of depression and anxiety: association with poor quality of life in 
type 1 and 2 diabetic patients. Clin Pract Epidemiol Ment Health 
2013;9:136–41.
 24 Rubin RR, Peyrot M. Psychological issues and treatments for people 
with diabetes. J Clin Psychol 2001;57:457–78.
 25 Baumeister H, Hutter N, Bengel J. Psychological and 
pharmacological interventions for depression in patients with 
diabetes mellitus: an abridged cochrane review. Diabet Med 
2014;31:773–86.
 26 Lustman PJ, Griffith LS, Clouse RE, et al. Effects of alprazolam on 
glucose regulation in diabetes. Results of double-blind, placebo-
controlled trial. Diabetes Care 1995;18:1133–9.
 27 Khuwaja AK, Lalani S, Dhanani R, et al. Anxiety and depression 
among outpatients with type 2 diabetes: a multi-centre study 
of prevalence and associated factors. Diabetol Metab Syndr 
2010;2.
 28 Wittchen HU, Müller N, Pfister H, et al. [Affective, somatoform and 
anxiety disorders in Germany--initial results of an additional federal 
survey of "psychiatric disorders"]. Gesundheitswesen 1999;61 Spec 
No:S216–22.
 29 Alosaimi FD, Alzain N, Asiri S, et al. Patterns of psychiatric diagnoses 
in inpatient and outpatient psychiatric settings in Saudi Arabia. Arch. 
Clin. Psychiatry 2017;44:77–83.
 30 Mirghani HO, Elbadawi AS. Depression, anxiety, and daytime 
sleepiness among type 2 diabetic patients and their correlation with 
the diabetes control: A case-control study. J Taibah Univ Med Sci 
2016;11:374–9.
 31 AlBekairy A, AbuRuz S, Alsabani B, et al. Exploring factors 
associated with depression and anxiety among hospitalized patients 
with type 2 diabetes mellitus. Med Princ Pract 2017;26:547–53.
 32 Kiejna A, Piotrowski P, Adamowski T, et al. [The prevalence of 
common mental disorders in the population of adult Poles by 
sex and age structure - an EZOP Poland study]. Psychiatr Pol 
2015;49:15–27.
 33 Volodina MN, Starostina EG, Moshnyaga EN, et al. 
Rasprostranennost' nepsihoticheskih psihicheskih rasstrojstv (NPR) 
pri saharnom diabete (SD). - V knige: Vzaimodejstvie specialistov 
v okazanii pomoshchi pri psihicheskih rasstrojstvah. Materialy 
obshcherossijskoj konferencii v ramkah Plenuma Pravleniya 
Rossijskogo obshchestva psihiatrov s uchastiem glavnyh psihiatrov 
i narkologov, rukovoditelej psihiatricheskih i narkologicheskih 
uchrezhdenij sub"ektov RF. - Otvetstvennyj redaktor Krasnov V.N 
2009:13–14.
 34 Starostina EG, Moshnyaga EN, Volodina MN, et al. Epidemiologiya 
naiboleye chastykh psikhicheskikh rasstroystv U bolnykh sakharnym 
diabetom. Almanakh klinicheskoy meditsiny 2014;32:17–23.
 35 Lloyd CE, Nouwen A, Sartorius N, et al. Prevalence and correlates of 
depressive disorders in people with type 2 diabetes: results from the 
International prevalence and treatment of diabetes and depression 
(INTERPRET-DD) study, a collaborative study carried out in 14 
countries. Diabet Med 2018;35:760–9.
 36 Lloyd CE, Sartorius N, Cimino LC, et al. The INTERPRET-DD study of 
diabetes and depression: a protocol. Diabet Med 2015;32:925–34.
 37 Sheehan DV, Lecrubier Y, Harnett Sheehan K, et al. The validity of the 
mini international neuropsychiatric interview (mini) according to the 
SCID-P and its reliability. European Psychiatry 1997;12:232–41.
 38 Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International 
neuropsychiatric interview (M.I.N.I.): the development and validation 
of a structured diagnostic psychiatric interview for DSM-IV and ICD-
10. J Clin Psychiatry 1998;59 Suppl 20:22–33.
 39 IBM CR. Ibm SPSS statistics for windows, version 23.0. Armonk, NY: 
IBM Corp, 2015.
 40 Li C, Barker L, Ford ES, et al. Diabetes and anxiety in US adults: 
findings from the 2006 behavioral risk factor surveillance system. 
Diabet Med 2008;25:878–81.
 41 Thomas J, Jones G, Scarinci I, et al. A descriptive and comparative 
study of the prevalence of depressive and anxiety disorders in 
low-income adults with type 2 diabetes and other chronic illnesses. 
Diabetes Care 2003;26:2311–7.
 42 Kessler RC, Angermeyer M, Anthony JC, et al. Lifetime prevalence 
and age-of-onset distributions of mental disorders in the world 
Health organization's world mental health survey initiative. World 
Psychiatry 2007;6:168–76.
 43 Trento M, Charrier L, Salassa M, et al. Depression, anxiety and 
cognitive function in patients with type 2 diabetes: an 8-year 
prospective observational study. Acta Diabetol 2015;52:1157–66.
 44 Anderson RJ, Grigsby AB, Freedland KE, et al. Anxiety and poor 
glycemic control: a meta-analytic review of the literature. Int J 
Psychiatry Med 2002;32:235–47.
 45 Zhang Y, Hu G, Yuan Z, et al. Glycosylated hemoglobin in 
relationship to cardiovascular outcomes and death in patients with 
type 2 diabetes: a systematic review and meta-analysis. PLoS One 
2012;7:e42551.
 46 Iversen MM, Nefs G, Tell GS, et al. Anxiety and depressive symptoms 
as predictors of all-cause mortality among people with insulin-naïve 
type 2 diabetes: 17-year follow-up of the second Nord-Trøndelag 
health survey (HUNT2), Norway. PLoS One 2016;11:e0160861.
 47 Aschner P. New IDF clinical practice recommendations for 
managing type 2 diabetes in primary care. Diabetes Res Clin Pract 
2017;132:170
9Chaturvedi SK, et al. General Psychiatry 2019;32:e100076. doi:10.1136/gpsych-2019-100076
General Psychiatry
Dr Santosh K Chaturvedi, MD, FRCPE [Edinburgh UK], FRCPsych [UK] is a Senior Professor of 
Psychiatry at the National Institute of Mental Health & Neurosciences, Bangalore, India. He was one of the 
principal investigators along with Professor Y Nakane in the International Collaborative Study on Quality 
of Life of Caregivers of Dementia patients, Japan, 1997 to 1999. He is the Editor-in-Chief of the Journal of 
Psychosocial Rehabilitation and Mental health, published by Springer Nature. His research interests include 
consultation liaison psychiatry, chronic pain & somatization, neuropsychiatry, quality of life research, 
psycho-oncology & palliative care, dementia, cultural psychiatry, instruments & scales development & 
translations, and postgraduate training & teaching methods. He has more than 550 publications in 
different international and national journals, with more than 280 citations / listings in PUBMED / 
MEDLINE; He has edited and / or published sixteen books, manuals or journals. H index 33; i10 index 111; Citations >4000
